Evaluating the Anti-inflammatory Efficacy of a Novel Bipyrazole Derivative in Alleviating Symptoms of Experimental Colitis
TMNB exhibits potent anti-inflammatory and immunomodulatory activities, suggesting that TMNB could be a new therapeutic agent for managing inflammatory bowel disease. This study supports the need for further clinical trials to explore TMNB's efficacy and safety in human subjects.
Authors
- Yousra Bseiso (ORCID: https://orcid.org/0000-0002-4346-5049)
- Abdelrahim M. Alqudah (ORCID: https://orcid.org/0000-0003-3721-8225)
- Sara Altaber
- Mohammed Wedyan (ORCID: https://orcid.org/0000-0002-8693-5506)
- Badriyah Shadid Alotaibi (ORCID: https://orcid.org/0000-0002-4066-5694)
- Esam Y. Qnais (ORCID: https://orcid.org/0000-0002-6203-4527)
- Omar Gammoh (ORCID: https://orcid.org/0000-0001-8801-2652)
- Mohammad Alqudah (ORCID: https://orcid.org/0000-0002-3953-1955)
Institutions
- Princess Nourah bint Abdulrahman University (SA)
- Jordan University of Science and Technology (JO)
- Hashemite University (JO)
- Arabian Gulf University (BH)
- Yarmouk University (JO)
Publication Details
- Journal
- Current Molecular Pharmacology
- Published
- 2024-11-27
- DOI
- https://doi.org/10.2174/0118761429333261241021034043
- Citations
- 5
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 2.75